Predictors for Use of Sentinel Node Biopsy and the Association with Improved Survival in Melanoma Patients Who Have Nodal Staging
| Autor: | Dale Han, Gang Han, Timothy D. Murtha |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Skin Neoplasms Sentinel lymph node 03 medical and health sciences 0302 clinical medicine Surgical oncology Biopsy Epidemiology medicine Humans 030212 general & internal medicine Melanoma Survival rate Aged Neoplasm Staging Aged 80 and over medicine.diagnostic_test Sentinel Lymph Node Biopsy business.industry Therapeutic effect Middle Aged Sentinel node medicine.disease Survival Rate Oncology 030220 oncology & carcinogenesis Female Surgery Lymph Nodes Radiology business Follow-Up Studies SEER Program |
| Zdroj: | Annals of Surgical Oncology. 25:903-911 |
| ISSN: | 1534-4681 1068-9265 |
| Popis: | It is unknown how many patients with localized melanoma undergo sentinel lymph node biopsy (SLNB) or if there is a therapeutic effect from performing nodal staging. We evaluated predictors for SLNB use and assessed if there was an association with improved survival in melanoma patients who had SLNB. The Surveillance, Epidemiology, and End Results database was queried for clinically node-negative melanoma cases ≥ 0.75 mm in thickness treated from 2010 to 2012. Clinicopathologic factors were correlated with SLNB use, overall survival (OS), and melanoma-specific survival (MSS). Overall, 13,703 cases were included. SLNB was performed in 1479 of 3439 thin cases (43.0%), 5810 of 8522 intermediate-thickness cases (68.2%), and 916 of 1742 thick cases (52.6%). On multivariable analysis, age ≥ 70 years, thickness 4 mm, head/neck or trunk tumor location, being unmarried, African American race, and residing in a county with a lower level of education were significantly associated with a lower likelihood of performing SLNB (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink